Development of a novel class of B-Raf(V600E)-selective inhibitors through virtual screening and hierarchical hit...

Area of Science:

• Oncology
• Molecular Biology
• Medicinal Chemistry

Background:

• Oncogenic mutations in signaling pathways drive cancer development.
• B-Raf protein kinase mutations, particularly B-Raf(V600E), are common in cancers like melanoma.
• The constitutively active B-Raf(V600E) mutant is a key target for cancer drug development.

Purpose of the Study:

• To develop novel, selective inhibitors targeting the B-Raf(V600E) oncogene.
• To identify compounds with improved potency and selectivity through virtual screening and medicinal chemistry.

Main Methods:

• Multi-step virtual screening to identify initial hit compounds.
• Hierarchical hit optimization including scaffold-based analogue searching.
• In vitro biochemical assays to determine inhibitor potency (IC50) and selectivity.
• Cytotoxicity assays on cancer cells harboring the B-Raf(V600E) mutation.

Main Results:

• Virtual screening identified nine hit compounds with low micromolar IC50 values against B-Raf(V600E).
• Medicinal chemistry optimization significantly enhanced inhibitor potency and selectivity.
• Compounds 22f and 22q demonstrated nanomolar IC50 values.
• These optimized compounds showed selective in vitro activity against B-Raf(V600E) and exclusive cytotoxicity in relevant cancer cells.

Conclusions:

• Novel B-Raf(V600E) selective inhibitors were successfully developed.
• The identified compounds exhibit potent and selective inhibition of the B-Raf(V600E) oncogene.
• These inhibitors represent promising therapeutic candidates for B-Raf(V600E)-driven cancers, including melanoma.